2. Gene
  3. Scly - selenocysteine lyase Gene

Scly - selenocysteine lyase Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

种属: Mus musculus

同用名: SCL; Scly1; Scly2; 9830169H08; A930015N15Rik

基因 ID: 50880 | 基因类型: protein coding

关于 Scly

功能概要

Predicted to enable several functions, including protein homodimerization activity; selenocysteine lyase activity; and vitamin B6 binding activity. Acts upstream of or within several processes, including negative regulation of cellular response to oxidative stress; response to insulin; and selenium compound metabolic process. Predicted to be located in Golgi apparatus. Predicted to be part of catalytic complex. Is expressed in alimentary system; liver; and nervous system. Orthologous to human SCLY (selenocysteine lyase). [provided by Alliance of Genome Resources, Apr 2022]

Scly 基因产物(1)

mRNA Protein Name
NM_016717.3 NP_057926.2 selenocysteine lyase
基因本体论
  • 生物过程
生物过程 GO 注释 逻辑证据 参考文献 来源
acts upstream of or within lipid metabolic process IMP
IMP: 通过突变表型推断
22890841 MGI
acts upstream of or within negative regulation of cellular response to oxidative stress IMP
IMP: 通过突变表型推断
22890841 MGI
acts upstream of or within response to insulin IMP
IMP: 通过突变表型推断
22890841 MGI
acts upstream of or within selenium compound metabolic process IMP
IMP: 通过突变表型推断
22890841 MGI
EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断
蛋白主名 其他名称

selenocysteine lyase

mSCL

selenocysteine lyase

Selenocysteine reductase

selenocysteine reductase

相关产品

Approval
生物活性分子 (10)
目录号 产品名 作用方式
纯度 是否罕见病
HY-B0361 Aspartame 99.70% 否
HY-17474 Parecoxib Inhibitor 99.29% 是
HY-132587 Fitusiran 94.74% 否
HY-17474A Parecoxib Sodium Inhibitor 99.61% 是
HY-17509 Deracoxib 99.65% 否
HY-B0561R Spironolactone (Standard) 98.55% 否
HY-B0318A Metronidazole hydrochloride 98.44% 是
HY-B0455A Lomefloxacin 99.99% 否
HY-B0455AR Lomefloxacin (Standard) Inhibitor / 否
HY-B0455B Lomefloxacin (aspartate) Inhibitor / 否
抗体抑制剂 (1)
目录号 产品名 作用方式
纯度 是否罕见病
HY-P99590 Sotatercept 99.94% 否
Clinical Phase
生物活性分子 (14)
目录号 产品名 作用方式
纯度 Phase
HY-19834 Fenebrutinib Inhibitor 99.89% Phase 3
HY-132257 Rovalpituzumab tesirine Inhibitor 97.47% Phase 3
HY-136657 SC-43 99.01% Phase 2
HY-16012A Domatinostat 99.34% Phase 2
HY-14718 Resminostat Inhibitor 99.84% Phase 2
HY-16012 Domatinostat tosylate 99.66% Phase 2
HY-106395 Telinavir Inhibitor 98.16% Phase 2
HY-100934 SC-9 Activator 99.33% Phase 2
HY-19046 AGN-2979 hydrochloride Inhibitor / Phase 2
HY-19080 SC-45662 Inhibitor / Phase 2
HY-19500 SC-75416 Inhibitor / Phase 2
HY-16451 SC-49483 / Phase 2
HY-170554 ABBV-706 Inhibitor 99.71% Phase 1
HY-19163 SC-52012 Antagonist / Phase 1
抗体抑制剂 (1)
目录号 产品名 作用方式
纯度 Phase
HY-P99886 Pexelizumab Inhibitor 99.0% Phase 3
Pre-clinical Phase
生物活性分子 (164)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-18749 SC79 Activator 98.0% 否
HY-107410 SC-26196 Inhibitor 99.66% 否
HY-10496 SC75741 Inhibitor 99.24% 否
HY-148559 4A3-SC8 99.93% 否
HY-145799 5A2-SC8 Chemical 99.89% 否
HY-15614 SC144 99.48% 否
HY-W004283 Pentadecanoic acid 99.94% 否
HY-59105 SC-560 Inhibitor 99.79% 否
HY-13802 SC-514 Inhibitor 99.97% 否
HY-145758 FEN1-IN-SC13 Inhibitor 98.42% 否
HY-124876 SynuClean-D Inhibitor 99.89% 否
HY-161409 SC912 99.13% 否
HY-W591424 m-PEG-NHS ester (MW 2000) Ligand 98.0% 否
HY-126681 SC-VC-PAB-MMAE 99.07% 否
HY-15614A SC144 hydrochloride 98.98% 否
HY-103226 SC-57461A Inhibitor 99.93% 否
HY-19832 SC66 99.65% 否
HY-W010983 SC-236 99.59% 否
HY-18086 TCS PIM-1 1 Inhibitor 98.40% 否
HY-P0323A GP(33-41) TFA Inhibitor 99.62% 否
HY-108562 SC-51322 Antagonist 98.93% 否
HY-Y0079S D-Phenylalanine-d5 99.87% 否
HY-100931 SC-10 Activator 99.59% 否
HY-158031 PLK1/BRD4-IN-5 98.80% 否
HY-164373 SC428 98.0% 否
HY-101955A (2R,6R)-Hydroxynorketamine hydrochloride 99.91% 否
HY-144880 SC209 Inhibitor 98.99% 否
HY-108563A SC 51089 free base Antagonist 98.60% 否
HY-131236 EBNA1-IN-SC7 99.92% 否
HY-155656 Anti-inflammatory agent 49 Inhibitor 98.26% 否
HY-W013164 SC-58125 Inhibitor 99.92% 否
HY-Y0079S1 D-Phenylalanine-d8 98.28% 否
HY-114857 Clofencet 98.62% 否
HY-120113 SC-2001 99.37% 否
HY-124858 SC99 98.90% 否
HY-19897 4SC-203 Inhibitor 98.98% 否
HY-P10827 PIC1 PA Inhibitor 98.37% 否
HY-177069 4A3-SC7 98.55% 否
HY-118827 Vedaprofen Inhibitor 98.73% 否
HY-129982 SC-435 99.14% 否
HY-138865 BiCAPPA Inhibitor 98.35% 否
HY-145799A 5A2-SC8 TFA Chemical 98.56% 否
HY-102065 SC-19220 Antagonist 99.86% 否
HY-N9319 Fulvotomentoside A 99.76% 否
HY-W004297 1-Nonadecanol 99.16% 否
HY-132306 CCF0058981 Inhibitor 98.02% 否
HY-148194 SC239 99.97% 否
HY-124775 (S)-C33 Inhibitor 99.46% 否
HY-126693 SC-VC-PAB-DM1 97.04% 否
HY-B0561S Spironolactone-d7 99.96% 否
HY-B0561S1 Spironolactone-d3 99.82% 否
HY-47968 SC209 intermediate-1 ≥96.0% 否
HY-106395A (Rac)-Telinavir Inhibitor / 否
HY-108563 SC 51089 Antagonist / 否
HY-148402 p53 Activator 3 Activator 98.35% 否
HY-148404 p53 Activator 5 Activator 98.43% 否
HY-148528 SC-VC-PAB-N-Me-L-Ala-Maytansinol 98.66% 否
HY-171099 SC-919 Inhibitor 98.68% 否
HY-B0455S Lomefloxacin-d5 hydrochloride 99.88% 否
HY-P3326A Targeting the bacterial sliding clamp peptide 46 TFA Inhibitor 99.83% 否
HY-W009934 2-Phenyl-2-(2-pyridyl)acetonitrile 99.97% 否
HY-W028047 JFD01307SC Inhibitor 98.0% 否
HY-U00129 SC57666 Inhibitor 98.94% 否
HY-U00232 Bidisomide 99.62% 否
HY-100857 PrPSc-IN-1 / 否
HY-B0361S1 Aspartame-d5 / 否
HY-14398GL Celecoxib (GMP Like) Inhibitor / 否
HY-14908A Vidofludimus hemicalcium / 否
HY-105052 SC 34301 / 否
HY-105894 SC-42867 Antagonist / 否
HY-10828 SC-57461 Inhibitor / 否
HY-111251 4SC-207 / 否
HY-112739 SC-41930 Agonist / 否
HY-112740 SC-53228 Antagonist / 否
HY-113727 SC-39070 Antagonist / 否
HY-114786 SC-44463 Inhibitor / 否
HY-115360 IND45193 Inhibitor / 否
HY-117896 SC-50605 Antagonist / 否
HY-118795 SC-22716 Inhibitor / 否
HY-120053 SC-53606 Antagonist / 否
HY-120776 SC-51316 Antagonist / 否
HY-120794 SC-67655 / 否
HY-121598 Actisomide Inducer / 否
HY-122134 SC-58272 Inhibitor / 否
HY-123014 (Rac)-SC-45694 Agonist / 否
HY-123014A SC-45694 lithium / 否
HY-123229 Ropizine / 否
HY-123864 SC-68448 Antagonist / 否
HY-124985 VU6010608 Modulator / 否
HY-125494 Droxinavir hydrochloride Inhibitor / 否
HY-125494A Droxinavir Inhibitor / 否
HY-126667 SC-Val-Cit-PAB / 否
HY-129782 SC-55858 / 否
HY-139678 SC13 Agonist / 否
HY-14237 SC-77964 Inhibitor / 否
HY-156271 Tubulin polymerization-IN-52 Inhibitor / 否
HY-162791 (1s,4s)-C1-Piperidine-C1-cyclohexane-C1 / 否
HY-164525 SD-7300 Inhibitor / 否
HY-168730 Anticancer agent 259 Modulator / 否
HY-172133 HDAC3-IN-6 / 否
HY-172887 Kv7.2/Kv7.3 activator-2 Activator / 否
HY-172944 GPR40 Activator 3 Activator / 否
HY-17474AS Parecoxib-d5 sodium Inhibitor / 否
HY-17474S Parecoxib-d3 Inhibitor / 否
HY-174808 SC691 Inhibitor / 否
HY-17509S Deracoxib-d3 / 否
HY-175318S p53 Activator 15 Activator / 否
HY-176065 Nav1.2-IN-1 Inhibitor / 否
HY-178732 AB-22 Inhibitor / 否
HY-181980 SPB07393SC Inhibitor / 否
HY-182309 SC83288 Inhibitor / 否
HY-185426 ABBV-011 / 否
HY-400056 SC209 intermediate-2 99.60% 否
HY-B0561S2 Spironolactone-d3-1 / 否
HY-D2996 BOD-NH-SC / 否
HY-E70596 endo-α-1,5-Arabinanases, Paenibacillus polymyxa SC2 / 否
HY-N12229 Penipurdin A Inhibitor / 否
HY-N12871 Floramanoside D Inhibitor / 否
HY-N15703 Norisocorydine / 否
HY-N16606 2,4-Dihydroxy-6-methoxy-3,5-diprenylacetophenone Inhibitor / 否
HY-N17737 Floramanoside F / 否
HY-N9229 Myricadenin A Inhibitor / 否
HY-P3326 Targeting the bacterial sliding clamp peptide 46 Inhibitor / 否
HY-RS12473 SC5D Human Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS12514 SCLY Human Pre-designed siRNA Set A Pre-designed Set / 否
HY-W1130429 4A3-SC10 / 否
HY-W717425 SC-60 / 否
HY-W777079 Valdecoxib-13C2,15N / 否
HY-112333 SC-68376 Inhibitor / 否
HY-117717 (Rac)-SC-31391 Activator / 否
HY-118827S Vedaprofen-d3 Inhibitor / 否
HY-120045A DuP 747 hydrochloride / 否
HY-120550 RS 49676 Inhibitor / 否
HY-120586 SC-46944 Inhibitor / 否
HY-122288 SC 28538 Inhibitor / 否
HY-123156 SC-23110 Inhibitor / 否
HY-123354 SC 44914 Inhibitor / 否
HY-123747 SC-53116 Agonist / 否
HY-123747A SC-53116 hydrochloride Agonist / 否
HY-137089 Azacosterol dihydrochloride Inhibitor / 否
HY-137225 HTS07944 / 否
HY-157405 DENV-IN-11 Inhibitor / 否
HY-163631 Antibacterial agent 218 Inhibitor / 否
HY-168776 (S)-C12-200 / 否
HY-170520 Antibiofilm agent-14 Inhibitor / 否
HY-172411 GLP-1R agonist 29 Agonist / 否
HY-172536 m-PEG-NHS ester (MW 30000) / 否
HY-17474S1 Parecoxib-d5 Inhibitor / 否
HY-175697 Glycosyltransferase-IN-2 Inhibitor / 否
HY-180145 Furin-IN-3 Inhibitor / 否
HY-181494 FAPI-X5 Inhibitor / 否
HY-B0361S Aspartame-d3 / 否
HY-N12164 Linearmycin B Inhibitor / 否
HY-N14006 Louisianin D / 否
HY-N14139 Dioxamycin Inhibitor / 否
HY-N14632 Louisianin A / 否
HY-N14633 Louisianin B / 否
HY-N14634 Louisianin C / 否
HY-RS19952 Scly Mouse Pre-designed siRNA Set A Pre-designed Set / 否
HY-RS26454 Scly Rat Pre-designed siRNA Set A Pre-designed Set / 否
HY-W703540 Deracoxib-d4 / 否
HY-P0323 GP(33-41) Inhibitor / 否
HY-U00200 Dicirenone Antagonist / 否
HY-U00239 SC58451 Inhibitor / 否
抗体抑制剂 (3)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-P991041 Turmetabart 99.75% 否
HY-P99506 Tamrintamab 98.51% 否
HY-P990664 Anti-Melanotransferrin/CD228 Antibody / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens Scly NCBI NCBI:51540
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z